Themis Medicare vs Peers
- Market cap
- ₹1,012 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹79.08 – ₹148.27
Themis Medicare ranks 1st by market capitalisation among 1 Drug Manufacturers - Specialty & Generic companies tracked by ATS. Its largest peers are Themis Medicare. Its P/E of 22.5 compares with a peer median of 22.5.
Themis Medicare vs Drug Manufacturers - Specialty & Generic peers
Sorted by market capitalisation.
| Company | Close (₹) | 1D | Market cap (₹ cr) | P/E | P/B | ROE | 1Y return |
|---|---|---|---|---|---|---|---|
| Themis Medicare | 109.83 | -4.88% | 1,012 | 22.5 | 2.85 | 14.5% | +18.5% |
| Themis Medicare | 109.83 | -4.88% | 1,012 | 22.5 | 2.85 | 14.5% | +24.5% |
Source: NSE end-of-day prices; ratios from company filings. Data as of 9 October 2026. How this data is compiled.
Themis Medicare peer comparison — frequently asked questions
Who are Themis Medicare's competitors?
Themis Medicare's listed peers in Drug Manufacturers - Specialty & Generic include Themis Medicare, ranked here by market capitalisation.
How does Themis Medicare's P/E compare with its peers?
Themis Medicare trades at a P/E of 22.5, against a median of 22.5 across the 1 Drug Manufacturers - Specialty & Generic peers shown.
Which is the largest company among Themis Medicare's peers?
By market capitalisation, the largest company in the group is Themis Medicare at ₹1,012 crore, against ₹1,012 crore for Themis Medicare.
Same Data For Peers
Trade Themis Medicare With ATS
Track THEMISMED live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.